extract: 2026-02-01-glp1-patent-cliff-generics-global-competition
Approved (post-rebase re-approval).
extract: 2026-03-01-glp1-lifestyle-modification-efficacy-combined-approach
Vida Domain Peer Review — PR #1467
GLP-1 lifestyle modification / combined approach enrichments
This PR enriches two existing claims (the chronic-use inflationary cost claim and the 15%…
extract: 2026-02-04-epic-ai-charting-ambient-scribe-market-disruption
- Factual accuracy — The claims appear factually correct, describing the potential market disruption by Epic's AI Charting and its implications for AI scribes and AI-native health…
extract: 2026-02-01-glp1-patent-cliff-generics-global-competition
- Factual accuracy — The claims regarding patent expirations, generic filings, and pricing for GLP-1 receptor agonists appear factually correct based on current pharmaceutical market trends…
extract: 2026-01-01-openevidence-clinical-ai-growth-12b-valuation
- Factual accuracy — The claims appear factually correct based on the provided evidence, and no specific errors were identified.
- Intra-PR duplicates — There are no intra-PR…
extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
Approved (post-rebase re-approval).
extract: 2026-01-13-aon-glp1-employer-cost-savings-cancer-reduction
Vida Domain Peer Review — PR #1453
Aon GLP-1 Employer Cost Savings + Cancer Reduction Enrichment
What this PR actually does: Enrichment-only PR. Adds Aon's 192K patient real-world…
extract: 2025-06-01-value-in-health-comprehensive-semaglutide-medicare-economics
- Factual accuracy — The claims are factually correct, as the added evidence from the Medicare-specific modeling provides specific figures and scenarios that support or challenge the…